Tokyo, Oct. 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063205) titled 'Effects of Combined Ingestion of Arginine and Citrulline on Resistance Exercise Performance and Muscle Soreness' on Oct. 7.

Study Type: Interventional

Study Design: Basic Design - Cross-over Randomization - Randomized Blinding - Double blind -all involved are blinded Control - Placebo

Primary Sponsor: Institute - Juntendo University

Condition: Condition - Healthy adults (Volleyball players / Resistance-trained males) Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To evaluate the acute effects of combined L-arginine (Arg) and L-citrulline (Cit) ingestion (low dose: 1.5g each; high dose: 5.0g each) on high-intensity resistance exercise performance (total repetitions in back squat and bench press at 70% 1RM) and post-exercise muscle soreness (VAS at 24, 48, and 72 hours) in healthy resistance-trained adult males using a randomized, double-blind, placebo-controlled crossover trial. Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - Test Food A (Low-dose combination): Single ingestion of 100 mL beverage containing low doses of L-arginine and L-citrulline 60 minutes prior to exercise. Washout period is at least 7 days. Interventions/Control_2 - Test Food B (High-dose combination): Single ingestion of 100 mL beverage containing high doses of L-arginine and L-citrulline 60 minutes prior to exercise. Washout period is at least 7 days.

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not applicable Gender - Male Key inclusion criteria - 1) Male athletes / volleyball players belonging to a University Men's Volleyball Club or equivalent. 2) Able to comply with and complete all study protocols and scheduled visits. 3) Provided written informed consent after receiving and fully understanding explanations of the study. Key exclusion criteria - 1) Medical history or current presence of severe cardiac, hepatic, renal, or gastrointestinal diseases. 2) Surgical operations within 6 months prior to consent that may affect study outcomes (e.g., colonoscopic surgery, cholecystectomy). 3) Known allergy to study foods or ingredients. 4) Deemed unsuitable for participation by the principal or co-investigator. Target Size - 30

Recruitment Status: Recruitment status - No longer recruiting Date of protocol fixation - 2026 Year 05 Month 07 Day Date of IRB - 2026 Year 05 Month 07 Day Anticipated trial start date - 2026 Year 08 Month 01 Day Last follow-up date - 2026 Year 10 Month 15 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072340

Disclaimer: Curated by HT Syndication.